The Cardiovascular Information System Market in 2026

Before you write a word of your plan, get one definition right, because most business plan templates get it wrong. A cardiovascular information system, or CVIS, is software. It is the clinical system a cardiology department uses to capture, store, report, and analyse everything that happens across echocardiography, the catheterisation lab, hemodynamics, electrocardiography, nuclear cardiology, and structured reporting. It is not a clinic. You are not buying an exam room and a stress-test treadmill; you are building a product that hospitals license, integrate, and run for years.

That distinction changes the entire economic model. A cardiology clinic sells consultations. A CVIS company sells recurring software subscriptions, implementation, and integration services to health systems. The cost base is engineering and regulatory work, not medical consumables. Investors read a plan very differently depending on which of these two businesses you are actually describing, so the first job of your plan is to make the software nature unmistakable.

The global CVIS market was valued at roughly $1.3 billion in 2024 and is projected to grow at about 8.4% a year through 2030, which would take it toward $2.1 billion by the end of the decade (Grand View Research, 2024). North America is the largest region, driven by high procedure volumes and a mature reimbursement environment, while Europe and Asia-Pacific are the fastest-growing on the back of hospital digitisation programmes.

The underlying demand driver is not going away. Cardiovascular disease remains the leading cause of death worldwide, accounting for around 17.9 million deaths a year (World Health Organization, 2024). More procedures mean more imaging, more reporting, and more data that has to live somewhere structured and auditable. Every echo study, every cath-lab run, every ECG generates records a hospital is legally required to keep and increasingly wants to analyse. That is the whitespace a CVIS occupies.

The competitive picture matters for positioning. The category is dominated by large medical-technology firms: GE HealthCare (Centricity Cardio Enterprise and the MUSE ECG line), Philips (IntelliSpace Cardiovascular, formerly Xcelera), Siemens Healthineers (syngo Dynamics), Change Healthcare (Merge Cardio), Fujifilm (Synapse Cardiovascular), and Agfa HealthCare. These are capable, entrenched, and expensive, and they are slow. Their strength is enterprise reach and existing hospital relationships. Their weakness, and the gap most new entrants aim at, is a cloud-native architecture, a fast implementation, modern reporting, and pricing that fits the mid-size cardiology departments the majors under-serve. Your plan should name the specific soft underbelly you intend to exploit, not claim you will beat everyone at everything.

For related product categories that share the same buyer and integration challenges, it is worth reviewing our clinical information systems business plan template and the PACS and radiology information systems plan, since a hospital that buys one of these often evaluates the others in the same cycle.

Who Actually Buys a CVIS

A common weakness in early CVIS plans is describing "hospitals" as the customer, as if a hospital were a single decision-maker. It is not. A CVIS purchase runs through a buying committee, and your plan needs to show you understand who sits on it and what each person cares about. The clinical champion is usually a consultant cardiologist or the cardiac-imaging lead who wants faster reporting and fewer clicks per study. The cardiology department manager owns throughput and staffing and wants to know the system will not create bottlenecks. The chief information officer and clinical-safety officer care about integration, data protection, and whether the product passes their security and clinical-safety review. And procurement and finance care about total cost of ownership over a five-year contract, not the sticker price.

The practical consequence is that you are selling three different stories to three different audiences inside one account, and your plan should reflect that. The clinical story is about time saved per report and diagnostic confidence. The IT story is about interoperability, uptime, and security posture. The finance story is about a predictable subscription that replaces a capital-heavy legacy system. Founders who win in this category build sales collateral for each of these buyers and quantify the value in the terms that buyer measures. A plan that names the committee, maps its incentives, and shows how you move it to a signed contract is far more persuasive to an investor than one that treats the sale as a single transaction.

Segment your market by department size, too. A regional teaching hospital with a busy cath lab and thousands of echo studies a year is a different buyer from a small district cardiology unit running a few hundred. The former justifies a full enterprise deployment; the latter may only ever adopt a lean cloud subscription. Your revenue model, and the sales effort you can afford per account, should follow from that segmentation rather than a single blended assumption.

Funding a Health-IT Company: SBA Data & Realistic Routes

A CVIS company is a health-IT software business, which sits under NAICS 511210 (software publishers) or 541511 (custom programming), not a healthcare-provider code. That matters because lenders and investors judge you against software benchmarks: revenue quality, retention, gross margin, and the size of the regulatory moat, rather than against clinic occupancy rates.

In the United States, the SBA 7(a) loan programme remains a viable route for the working-capital and payroll portion of a software build, with loans up to $5 million and terms up to 10 years for working capital and 25 years when real estate is involved. Software firms without hard collateral typically borrow in the $150,000 to $500,000 band, and lenders will expect a lender-ready plan with monthly Year-1 projections, a clear use-of-funds table, and a founder capital injection of around 10 to 20 percent. The SBA 504 programme is less relevant here because it is geared to fixed assets. For pure early-stage product risk, most CVIS founders pair a modest 7(a) facility with equity, because a bank will not underwrite pre-revenue R&D on cash flow alone.

In the United Kingdom, the government-backed Start Up Loans scheme offers up to £25,000 per founder at 6% fixed interest with free mentoring, which realistically covers a slice of early salaries rather than a full build. The more consequential UK routes for a CVIS are the SEIS and EIS tax-advantaged investment schemes, which let angels and early funds claim income-tax relief and make a health-IT raise materially easier to close, plus non-dilutive Innovate UK grants aimed squarely at digital-health and medical-device innovation.

Whichever route you choose, the deciding factor is the same: a lender or investor needs to see that your recurring revenue, retention, and regulatory position justify the ask. A plan that shows a credible path from first pilot to repeatable multi-site sales is worth more than one that simply projects a large market. Our bespoke business plan service builds the SBA-formatted and SEIS-ready financials that these applications require.

What It Actually Costs to Build a CVIS

Reaching a market-ready product deployed at a first paying site typically costs $180,000 to $750,000 (£140,000 to £600,000). The range is wide because it depends heavily on one choice: whether your software makes diagnostic claims. A workflow-and-reporting CVIS that stops short of diagnosis can ship at the lower end. The moment you add a measurement or interpretation clinicians rely on, you inherit a quality system and a regulatory submission, and the budget climbs.

Unlike a clinic, almost none of this money goes on physical equipment. There is no sterilisation kit, no pharmaceutical stock, no fleasehold fit-out. The spend is people and compliance. Here is where the capital actually goes:

Build & Launch Cost Breakdown

• Core engineering team (18 months, 4–6 developers with DICOM/HL7 experience): $90K–$380K (£72K–£300K)
• Interoperability build (DICOM, HL7 v2, FHIR, IHE Cardiology profiles): $25K–$90K (£20K–£72K)
• Cloud or on-prem infrastructure + PACS-grade storage (year one): $18K–$70K (£14K–£56K)
• Regulatory & quality system (FDA SaMD / UKCA, ISO 13485, IEC 62304): $20K–$110K (£16K–£88K)
• Cybersecurity, HIPAA / UK GDPR compliance & penetration testing: $12K–$45K (£9K–£36K)
• Clinical pilot deployment & validation at first site: $8K–$35K (£6K–£28K)
• Sales, clinical evidence & six months of working capital: $7K–$20K (£3K–£20K)

The single most under-budgeted line, in almost every CVIS plan we review, is interoperability. Founders assume "we'll add integrations later." In reality, DICOM cardiology objects, HL7 v2 order-and-results messaging, and FHIR-based EHR integration are the product for a hospital buyer. A CVIS that cannot pull an ECG from the MUSE system, receive an order from the EHR, and push a validated echo report back into the patient record is not a product a health system can use. Budget for this early, staff it with people who have done it before, and treat each integration as a validated deliverable rather than a feature.

The second most common budgeting error is treating cybersecurity and data protection as an afterthought. A CVIS holds protected health information and cardiology imaging. Before any hospital signs, it will run a security review, often a full penetration test and a data-protection assessment. Failing that review late in a nine-month sales cycle can cost you the deal and the year. Fund it up front so it is a strength in your pitch, not a scramble at the finish line.

Deployment Models: Which CVIS Are You Building?

"Cardiovascular information system" is not one business model. There are at least three distinct shapes, each with a different cost base, sales motion, and buyer. Your plan should state clearly which one you are building, because the financials, the team, and the regulatory exposure differ sharply between them.

Most successful new entrants start with the modular or cloud-native model, because both let you reach revenue before you have built an all-encompassing enterprise suite. Selling a narrow, excellent structured-reporting module into departments that already own a clunky incumbent is a far shorter path than displacing GE HealthCare or Philips wholesale. The enterprise on-prem model is the incumbents' home turf; win there only once you have reference sites and the balance sheet to survive an 18-month sales cycle.

From Concept to First Paying Site: A Realistic Timeline

One reason CVIS financial models fall apart under scrutiny is an over-optimistic timeline. A hospital does not adopt clinical software the way a small business adopts a productivity tool. Build the plan around a sequence that a health-IT investor will recognise as honest:

• Months 0–6: architecture and core build. Hire the engineering team, design the data model for cardiology objects, and stand up the DICOM and HL7 foundations. This is the period of pure burn with no revenue, and your funding must cover it.
• Months 6–12: first integrations and a pilot. Secure a design-partner cardiology department, build the specific integrations their environment demands, and deploy in a validated pilot. Expect the pilot to be unpaid or heavily discounted in exchange for a reference and clinical feedback.
• Months 12–18: clinical validation and security review. Pass the hospital's clinical-safety case and security assessment, gather evidence that reporting time and data quality improve, and, if you make diagnostic claims, progress the device submission in parallel.
• Months 18–30: first paid contracts and repeatability. Convert the pilot to a paid contract, use it as a reference to shorten the next sales cycles, and start building the repeatable playbook that turns a bespoke first sale into a scalable second and third.

Compress this in your model at your peril. The founders who raise successfully are the ones whose cash-flow forecast assumes the first meaningful revenue lands well over a year after funding, and who show they have the runway to reach it. A plan that promises revenue in the first quarter tells an experienced investor you have never sold to a hospital.

Pricing, Revenue Streams & Unit Economics

A CVIS earns through three connected streams. The first is recurring subscription, usually a per-site annual licence of roughly $40,000 to $180,000 (£32,000 to £145,000) scaled by modules, procedure volume, or bed count. The second is one-off implementation, typically $15,000 to $80,000, covering integration, data migration, configuration, and clinical validation. The third is ongoing services: additional integrations, training, support tiers, and analytics add-ons. Some vendors also charge per study or per exam, which aligns cost with usage and can lower the barrier for smaller departments.

The economics are attractive once the platform exists because the marginal cost of adding a site is low, driving gross margins toward 68 to 82 percent at scale. The catch is time-to-revenue: the enterprise sales cycle runs 9 to 18 months, so early cash burn is real and your plan must show you can survive it.

A Worked Example

Take a vendor that has built its platform and closed its first reference sites. In Year 2 it signs 12 mid-size cardiology departments at an average subscription of $75,000 a year plus an average $30,000 implementation fee. That is $900,000 of recurring ARR plus $360,000 of services, roughly $1.26 million in Year-2 revenue. At a 74% gross margin and disciplined headcount, that model supports a credible path to breakeven around 20 to 24 months after first revenue. Push the average subscription to $90,000 and add net-revenue retention from module expansion, and the same 12 accounts become a base you can grow without proportionally growing sales cost, which is exactly the compounding investors want to see.

The numbers that decide whether this business is fundable are not the market size; they are net revenue retention, gross margin, CAC payback, and the ratio of implementation revenue to subscription revenue. A plan that quantifies those, rather than repeating "the market is large and growing," is the one that gets funded. Our market research and content service builds these unit-economics assumptions with defensible sourcing.

Why Retention Is the Whole Game

In a CVIS business, the first sale is expensive and slow, but the renewal is where the money is. Once your software is embedded in a cardiology department's daily reporting workflow, integrated with its PACS and EHR, and holding years of the department's cardiology records, the switching cost for the hospital is enormous. Ripping out a CVIS means re-validating every integration, re-training staff, and migrating protected clinical data. That stickiness is exactly why incumbents keep accounts for a decade or more, and it is the asset that makes a CVIS company valuable.

For your plan, this means retention and expansion revenue deserve more attention than raw new-logo growth. A vendor that keeps 95 percent of its sites and grows each account by selling additional modules, more storage, or analytics upgrades compounds far faster than one that churns and refills. Model net revenue retention explicitly, show the expansion path (a department that starts with reporting adds cath-lab hemodynamics, then an analytics layer), and demonstrate that your gross-margin structure improves as accounts mature. Investors in health-IT are pattern-matching for this. A business that behaves like enterprise infrastructure, not like a one-time software sale, earns a higher multiple and an easier raise.

Regulatory & Compliance Pathways

Regulation is where CVIS plans most often go wrong, in both directions. Some founders ignore it entirely and describe a diagnostic product with no device pathway. Others assume every feature needs full medical-device clearance and price themselves out of a launch. The truth is nuanced and hinges on your claims: what you tell a clinician the software does. Workflow, archiving, and reporting are frequently non-diagnostic. A measurement, calculation, or interpretation a clinician relies on for diagnosis is Software as a Medical Device, and it is regulated.

United States

• FDA Software as a Medical Device (SaMD): a 510(k) clearance may be required if the software makes diagnostic measurements or interpretations. Budget $12K–$120K in preparation and expect a 3–12 month review with the FDA's Center for Devices and Radiological Health (CDRH).
• HIPAA Security & Privacy Rule: mandatory for any system holding protected health information; enforced by the HHS Office for Civil Rights. Plan for ongoing compliance, not a one-time cost.
• ONC Health IT Certification: relevant if you want to participate in interoperability incentive programmes; performed through authorised test labs.

United Kingdom

• UKCA marking (MHRA): medical-device software is typically Class I or IIa; a Class IIa diagnostic module requires conformity assessment. Budget £10K–£90K over a 4–12 month path.
• DTAC (Digital Technology Assessment Criteria): the NHS England baseline for clinical safety, data protection, technical security, interoperability, and usability. Effectively a gate for NHS supply; plan 6–12 weeks.
• DSPT and UK GDPR: the NHS Data Security and Protection Toolkit plus data-protection compliance under the ICO; ongoing and non-negotiable for handling patient data.

European Union & International Standards

• EU MDR (Regulation 2017/745): CE marking for medical-device software, with Notified Body assessment for Class IIa and above. This is the pathway for selling into EU health systems.
• ISO 13485: the quality-management system standard expected of any serious medical-device software vendor.
• IEC 62304 & ISO 14971: the software-lifecycle and risk-management standards regulators and hospital buyers look for.
• ISO 27001: information-security certification that shortens hospital security reviews considerably.

A practical strategy many founders use, and one investors respond well to, is to separate the regulated diagnostic module from the unregulated workflow module. You ship the workflow, archiving, and reporting product first to generate revenue and reference sites, while the diagnostic module goes through its device pathway in parallel. This de-risks the raise and shortens time-to-revenue without cutting corners on safety. If you cite regulatory bodies in your plan, use the primary sources: the FDA on Software as a Medical Device and the MHRA guidance on software and app medical devices.

Five Mistakes That Sink CVIS Startups

Across the health-IT plans our team has reviewed, the same avoidable errors recur. Each one is easy to fix on paper and expensive to fix after you have raised on the wrong assumptions.

• Modelling it as a clinic. Budgeting for sterilisation gear, drug stock, and consultation fees signals to any investor that you do not understand your own category. A CVIS is enterprise software; the cost base is engineers and compliance, and the revenue is recurring licences.
• Under-budgeting interoperability. DICOM, HL7 v2, FHIR, and IHE Cardiology profiles are the hardest, most expensive engineering in the whole build, and they are non-optional. Treating integration as a "phase two" feature is how products die in procurement.
• Getting the regulatory scope wrong. Claiming a diagnostic capability with no device pathway will stall you at hospital clinical-safety review. The fix is to define claims precisely and separate regulated from unregulated modules.
• Modelling a short sales cycle. Health-system procurement runs 9 to 18 months, with security reviews, clinical-safety cases, and committee sign-off. A cash-flow forecast that assumes revenue in month three is not credible and will not survive investor diligence.
• Skimping on security and audit. Storing cardiology imaging without PACS-grade redundancy, audit trails, and encryption fails the hospital's security assessment. Build to the standard hospitals demand, then make it a selling point.

Sample Business Plan Preview

Here is an extract from a CVIS business plan structured the way lenders and health-IT investors expect. It shows the software framing, the regulatory strategy, and the numbers that actually get diligenced:

What's in the Template

Every Avvale business plan template includes these sections, pre-structured for your industry. For a CVIS, we frame each one around the software-and-compliance realities above rather than generic filler:

• Executive Summary — Your CVIS at a glance, written to make the software model and regulatory strategy unmistakable in the first 60 seconds.
• Company Overview — Legal structure, ownership, IP position, and the deployment model (cloud-native, on-prem, or modular) you are pursuing.
• Industry Analysis — CVIS market size, growth, the incumbent field, and the specific gap you are targeting.
• Customer Analysis — Cardiology departments, procedure volumes, buying committees, and procurement timelines.
• Competitor Analysis — Where GE HealthCare, Philips, Siemens Healthineers, Merge, Fujifilm, and Agfa are strong, and where they are beatable.
• Product & Regulatory Plan — Interoperability scope (DICOM, HL7, FHIR, IHE) and the FDA/UKCA/MDR pathway for any diagnostic claims.
• Operations Plan — Engineering roadmap, integration delivery, security, and validated deployment at each site.
• Management Team — Clinical and engineering credibility, advisory board, and the key hires a health-IT investor expects.

The optional Financial Forecast add-on (included in our $300/£250 and $1,000/£800 packages) provides a 5-year Excel model with income statement, cash flow, balance sheet, break-even analysis, SaaS metrics (ARR, net revenue retention, CAC payback), and startup capital requirements built for a software business.

Frequently Asked Questions